For a study, researchers sought to assess the pregnancy outcomes of women who underwent and did not receive comprehensive chromosomal screening-based preimplantation genetic testing for aneuploidy (PGT-A) in women receiving in vitro fertilization (IVF) therapy.

They looked for randomized controlled studies focused on PGT-A therapy without regard to language in Medline, EMBASE, the Cochrane Central Register of Controlled Trials, and between their commencement and February 28, 2022. Comprehensive chromosomal testing and randomized controlled trials, including women were having IVF with or without PGT-A. A random-effects model with the Mantel-Haenszel technique was used to determine pooled relative risks (RRs) with 95% confidence intervals for the primary outcome.

There were a total of 9 trials with 3,334 participants. PGT-A was generally not linked to a higher live birth rate (RR 1.13, 95% CI 0.96-1.34, I2=79%). PGT-A did not increase the live birth rate in women of nonadvanced age (RR 0.94, 95% CI 0.89-0.99, I2=0%), but it did in women of advanced maternal age (RR 1.34, 95% CI 1.02-1.77, I2=50%).

The rate of live births in women with advanced maternal age rose with preimplantation genetic testing for aneuploidy.